Adult Dosing
Chemotherapy induced febrile neutropenia
- Recommended dose of tbo-filgrastim is 5 mcg/kg per day administered as a subcutaneous injection
Notes:- Administer the first dose of tbo-filgrastim no earlier than 24 hours following myelosuppressive chemotherapy
- Do not administer tbo-filgrastim within 24 hours prior to chemotherapy
- Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Patient may develop splenic rupture on administration and may report upper abdominal or shoulder pain
- Patient may be evaluated for fever and lung infiltrates or respiratory distress after receiving therapy
- Serious allergic reactions may be seen in patients on tbo-filgrastim therapy
- Patient with sickle cell disease may experience severe and sometimes fatal crisis
- Tbo-filgrastim may exert tumor growth stimulatory effects on malignant cells including myeloid malignancies and myelodysplasia
Supplemental Patient Information
- Advise patients to inform about any signs of infection such as fever, redness or swelling
- Inform patients to avoid pregnancy while receiving tbo-filgrastim. If pregnancy occurs, advise patients of the possibility of fetal harm
Pregnancy Category:C
Breastfeeding: Unknown if excreted in human milk; nursing mothers should be cautioned before starting the therapy
